Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan O. Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

Blood (2017) 130 (5): 597–605.

https://doi.org/10.1182/blood-2017-03-771220

Published: 2017

Journal Articles

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

Vaishali Sanchorawala, Anthony C. Shelton, Stephen Lo, Cindy Varga, J. Mark Sloan, David C. Seldin

Blood (2016) 128 (8): 1059–1062.

https://doi.org/10.1182/blood-2016-04-710822

Published: 2016

Journal Articles

Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio

Tatiana Prokaeva, Brian Spencer, Fangui Sun, Nathaniel McConnell, Richard M O'hara, David C Seldin, Lawreen Connors, Vaishali Sanchorawala

Blood (2015) 126 (23): 2956.

https://doi.org/10.1182/blood.V126.23.2956.2956

Published: 2015

Journal Articles

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

Vaishali Sanchorawala, Fangui Sun, Karen Quillen, J. Mark Sloan, John L. Berk, David C. Seldin

Blood (2015) 126 (20): 2345–2347.

https://doi.org/10.1182/blood-2015-08-662726

Published: 2015

Journal Articles

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Stephen Lo, John Mark Sloan, MD, David C Seldin, MD PhD

Blood (2014) 124 (21): 3463.

https://doi.org/10.1182/blood.V124.21.3463.3463

Published: 2014

Journal Articles

Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients

John Mark Sloan, MD, Moussa Sissoko, MD, David C Seldin, MD PhD, Brian Sworder, MD, Kennneth Angelino, MD, Mike Broce, John L Berk, MD, Vaishali Sanchorawala, MD

Blood (2014) 124 (21): 4750.

https://doi.org/10.1182/blood.V124.21.4750.4750

Published: 2014

Journal Articles

Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis

Moussa Sissoko, MD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Brian Sworder, MD, John L Berk, MD, John Mark Sloan, MD

Blood (2013) 122 (21): 1991.

https://doi.org/10.1182/blood.V122.21.1991.1991

Published: 2013

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, Vaishali Sanchorawala

Blood (2012) 120 (22): 4445–4446.

https://doi.org/10.1182/blood-2012-09-457341

Published: 2012

Journal Articles

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Gheorghe Doros, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 1873.

https://doi.org/10.1182/blood.V120.21.1873.1873

Published: 2012

Journal Articles

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 2019.

https://doi.org/10.1182/blood.V120.21.2019.2019

Published: 2012

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Amyloidomics comes of age

David C. Seldin, Vaishali Sanchorawala

Blood (2012) 119 (8): 1795–1796.

https://doi.org/10.1182/blood-2011-10-381178

Published: 2012

Journal Articles

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

Jennifer Ellis Ward, Ruiyi Ren, Gianluca Toraldo, Pam SooHoo, Jian Guan, Carl O'Hara, Ravi Jasuja, Vickery Trinkaus-Randall, Ronglih Liao, Lawreen H. Connors, David C. Seldin

Blood (2011) 118 (25): 6610–6617.

https://doi.org/10.1182/blood-2011-04-351643

Published: 2011

Journal Articles

Doxycycline Reduces Fibril Formation in a Transgenic Mouse Model of AL Amyloidosis

David C Seldin, MD, PhD, Jennifer Ward, PhD, Ruiyi Ren, MSc, Gianluca Toraldo, PhD, Pamela T SooHoo, BA, Jian Guan, BS, Carl O'Hara, Ravi Jasuja, PhD, Vickery Trinkaus-Randall, PhD, Ronglih Liao, PhD, Lawreen H Connors, PhD

Blood (2011) 118 (21): 1837.

https://doi.org/10.1182/blood.V118.21.1837.1837

Published: 2011

Journal Articles

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Vaishali Sanchorawala, MD, Antje Hoering, PhD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli A Fennessey, Bassam I Mattar, MD, Hana F Safah, MD, Leona Holmberg, MD, PhD, Robert M. Dean, MD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 2004.

https://doi.org/10.1182/blood.V118.21.2004.2004

Published: 2011

Journal Articles

Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT)

Sarah Taimur, MD, Claudia Nader, MD, Christine Lloyd-Travaglini, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2041.

https://doi.org/10.1182/blood.V118.21.2041.2041

Published: 2011

Journal Articles

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Saulius Girnius, M.D., David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, John L Berk, MD, Frederick L Ruberg, MD, Hans Meier-Ewert, MD, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2043.

https://doi.org/10.1182/blood.V118.21.2043.2043

Published: 2011

Journal Articles

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, J. Mark Sloan, Kathleen T. Finn, Gheorghe Doros, Joan Blade, Martha Skinner

Blood (2011) 118 (16): 4346–4352.

https://doi.org/10.1182/blood-2011-01-330738

Published: 2011

Journal Articles

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Umit Tapan, David C. Seldin, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, Vaishali Sanchorawala

Blood (2010) 116 (23): 5071–5072.

https://doi.org/10.1182/blood-2010-09-305136

Published: 2010

NARROW

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study

Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients

Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Amyloidomics comes of age

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

Doxycycline Reduces Fibril Formation in a Transgenic Mouse Model of AL Amyloidosis

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT)

High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only